| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J9390 | Vinorelbine | Navelbine | 10 mg | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | No | 1994 | Jan 1, 1996 | In Use | ||
| NA | Uracil Mustard | Uramustine | unspecified | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1962 | 1999 | No Longer Used | ||
| J0594 | Busulfan | Busulfex | 1 mg | Chemotherapy | Alkylating Agent | Alkylsulfonate | No | 1999 | Jan 1, 2007 | In Use | ||
| NA | Sorafenib | Nexavar | 200 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR,KIT,RET, CRAF, BRAF | Yes | 2005 | In Use | |||
| NA | Sotorasib | Lumakras | Multiple | Chemotherapy | RAS Inhibitor | KRASG12C | Yes | 2021 | In Use | |||
| NA | ixazomib | Ninlaro | 3 mg | Chemotherapy | Proteasome Inhibitor | 20S | Yes | 2015 | In Use | |||
| Q5129 | Bevacizumab-adcd | Vegzelma | 10mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2023 | Mar 17, 2023 | In Use | ||
| J1380 | Estradiol Valerate | Delestrogen | 10 mg | Hormonal Therapy | Estrogen | No | 1954 | Jan 1, 1997 | In Use | |||
| NA | Lorlatinib | Lorbrena | 25mg, 100mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK/ROS1 | Yes | 2018 | In Use | |||
| J1952 | Leuprolide Mesylate | Camcevi | 1mg | Hormonal Therapy | GnRH Agonist | No | 2021 | Jan 26, 2022 | In Use | |||
| J9282 | Mitomycin Intravesical Instillation | Zusduri | 1mg | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | No | 2025 | Jan 1, 2026 | In Use | ||
| Momelotinib | Ojjaara | Multiple | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2023 | In Use | ||||
| C9492 | Durvalumab | Imfinzi | 10 mg | Immunotherapy | Checkpoint Inhibitor | PD-L1 | No | 2017 | Oct 1, 2017 | In Use | ||
| J9064 | Cabazitaxel (Sandoz) | Cabazitaxel | 1mg | Chemotherapy | Antimitotic Agent | Taxane | No | 2023 | Aug 28, 2023 | In Use | ||
| J2860 | Siltuximab | Sylvant | 10 mg | Immunotherapy | Monoclonal Antibody | IL-6 | No | 2014 | Jan 1, 2016 | In Use | ||
| NA | Cysteamine Bitartrate | Cystagon | 50mg, 150mg | Chemotherapy | Cystine-Depleting Agent | Yes | 1994 | In Use | ||||
| NA | Sunitinib malate | Sutent | 12.5 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR,KIT, RET, CSF | Yes | 2006 | In Use | |||
| J9266 | Pegaspargase | Oncaspar | unspecified | Chemotherapy | Miscellaneous Agent | Enzyme | No | 1994 | Jan 1, 1996 | In Use | ||
| J9181 | Etoposide | Toposar, Etopophos | 10 mg | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | No | 1983 | Jan 1, 1987 | In Use | ||
| S9338 | Immunotherapy - non specific | Home infusion therapy, immunotherapy | NA | Immunotherapy | No | Jan 1, 2002 | In Use | |||||
| Q0180 | Dolasetron Mesylate | Anzemet | 100 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Yes | 1997 | Apr 1, 1998 | In Use | ||
| J9047 | Carfilzomib | Kyprolis | 1 mg | Chemotherapy | Proteasome Inhibitor | 20S | No | 2012 | Apr 1, 2014 | In Use | ||
| J8522 | Capecitabine | Multiple | 50mg | Chemotherapy | Antimetabolite | Yes | 2005 | Sep 11, 2024 | In Use | |||
| J9341 | Thiotepa (tepylute) | Tepylute | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard /Ethylenimine | No | 2025 | Jul 9, 2025 | In Use | ||
| J9054 | Bortezomib (boruzu) | Boruzu | 0.1mg | Chemotherapy | Proteasome Inhibitor | 26S | No | 2024 | Mar 26, 2025 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home